Last updated: September 4, 2026
Levoleucovorin is a mature, off-patent oncology supportive-care drug with limited exclusivity, low differentiation, and primarily institutional demand. The U.S. market is shaped by generic competition, hospital purchasing, chemotherapy protocols, reimbursement economics, and periodic injectable-drug shortages rather than by patent protection. Revenue growth is unlikely to come from broad price expansion. The strongest commercial opportunities are supply reliability, contract manufacturing, hospital formulary access, and differentiated ready-to-use presentations.
What is levoleucovorin and how is it used?
Levoleucovorin is the pharmacologically active levo-isomer of folinic acid. It is administered primarily by injection in oncology settings.
The FDA-approved uses include:
- Rescue after high-dose methotrexate therapy.
- Combination treatment with 5-fluorouracil for metastatic colorectal cancer.
- Reduction of toxicity associated with folic-acid antagonists in certain clinical settings.
Fusilev was approved by the FDA in 2008. Khapzory was approved in 2018. Both products contain levoleucovorin calcium for injection and compete with racemic leucovorin products, which contain both active and less-active isomers. FDA labeling identifies levoleucovorin as the levo-isomer of folinic acid and specifies dosing differences relative to racemic leucovorin products. [1, 2]
The drug is not a biologic and does not face biosimilar competition. Its competitive set consists of:
- Generic levoleucovorin injection.
- Branded levoleucovorin products.
- Racemic leucovorin calcium injection.
- Oral or injectable folinic-acid alternatives where clinically appropriate.
- Protocol substitution and hospital formulary decisions.
What is the FDA regulatory status of levoleucovorin?
Levoleucovorin has full FDA approval for multiple oncology uses. The principal U.S. regulatory products are shown below.
| Product |
Active ingredient |
FDA status |
Primary sponsor or commercial source |
Dosage form |
| Fusilev |
Levoleucovorin calcium |
Approved |
Historically Spectrum Pharmaceuticals; later commercialized by oncology specialty companies |
Injection |
| Khapzory |
Levoleucovorin calcium |
Approved |
Spectrum Pharmaceuticals; later associated with Acrotech Biopharma |
Injection |
| Generic products |
Levoleucovorin calcium |
Approved through ANDA pathway |
Multiple generic manufacturers |
Injection |
Fusilev received FDA approval under NDA 022254 in 2008. Khapzory was approved under NDA 208194 in 2018. The products use the 505(b)(2) or full NDA framework for branded products, while later generic entrants rely on abbreviated new drug applications where applicable. [1, 2]
FDA approval does not create a current commercial moat. The principal barriers are manufacturing validation, sterile injectable compliance, drug-shortage management, hospital contracting, and reliable distribution.
What patents protect levoleucovorin?
Levoleucovorin does not have a meaningful active patent estate comparable with newer oncology drugs. Core composition and use claims are historically expired or commercially weak.
The patent position can be summarized as follows:
| Protection category |
Current commercial significance |
| Active pharmaceutical ingredient |
No meaningful composition-of-matter exclusivity |
| Racemic-versus-single-isomer distinction |
Historically relevant, but not a durable current barrier |
| Injectable formulation |
Limited protection; generic injectable competition is established |
| Colorectal-cancer use |
Old and largely expired use concepts |
| Methotrexate-rescue use |
Old and largely expired use concepts |
| Manufacturing processes |
Potentially relevant to cost, purity, yield, and supply, but not usually a market-blocking patent barrier |
| Orange Book patents |
No evident active patent barrier supporting long-term branded exclusivity |
The FDA Orange Book is the controlling source for listed patents and regulatory exclusivity. For a mature product such as levoleucovorin, the relevant review is product-specific because listed patents can differ by NDA and dosage presentation. [3]
When did levoleucovorin lose exclusivity?
Levoleucovorin lost its economically important exclusivity well before the current market period.
Fusilev entered the market as a branded oncology product in 2008. Any commercial value from the original approval, formulation positioning, or market exclusivity has since been eroded by generic and therapeutic substitution. Khapzory entered later, but its later approval did not establish a durable new composition-of-matter estate.
The practical exclusivity timeline is:
| Period |
Market event |
Commercial effect |
| 2008 |
FDA approval of Fusilev |
Branded launch and protocol adoption |
| 2008-2011 |
Initial branded commercial period |
Higher price and limited direct competition |
| 2011 onward |
Generic and therapeutic competition |
Price pressure and hospital purchasing leverage |
| 2018 |
FDA approval of Khapzory |
Additional branded presentation and supply option |
| 2020 onward |
Mature injectable market |
Volume driven by protocols and supply availability |
| Current market |
Off-patent competition |
Low likelihood of durable price expansion |
The exact launch timing of each generic depends on the manufacturer, dosage strength, and regulatory pathway. Patent litigation and Paragraph IV activity have not produced a durable market exclusion comparable with high-value oncology drugs.
How many patents cover levoleucovorin?
No commercially material patent cluster currently protects the active ingredient across the U.S. market.
Patent exposure is better assessed by product presentation than by molecule alone. Relevant categories include:
- Vial concentration and fill volume.
- Reconstitution or dilution instructions.
- Stability in infusion solutions.
- Container-closure systems.
- Manufacturing and purification methods.
- Label-specific methods of use.
These claims can create tactical litigation or design-around issues, but they generally do not prevent generic levoleucovorin from entering the market. Injectable products can also be protected indirectly through manufacturing know-how, process controls, sterile-facility capacity, and supply contracts.
Are there Paragraph IV challenges to levoleucovorin?
Paragraph IV litigation is not the principal current market risk for levoleucovorin. The product’s key patents are old, and generic competition has already established the commercial outcome.
For branded drugs with active Orange Book patents, a Paragraph IV certification can trigger a 30-month stay under the Hatch-Waxman framework. That mechanism has limited strategic importance here because:
- The core product is mature.
- Generic levoleucovorin products are already commercially available.
- The major value driver is institutional supply, not patent-protected pricing.
- Formulation or process claims are easier to design around than composition patents.
- Generic substitution can occur through hospital purchasing even when a branded product remains available.
A new entrant’s larger risks are FDA approval timing, sterile manufacturing inspection, product quality, contract access, and shortage-related allocation.
What is the Orange Book status of levoleucovorin?
The Orange Book remains relevant for confirming:
- NDA and ANDA status.
- Approved strengths and dosage forms.
- Listed patents, if any.
- Pediatric exclusivity or other regulatory exclusivity.
- Therapeutic-equivalence information for generic products.
Levoleucovorin does not have the Orange Book profile of a protected specialty drug. The principal market is a mature injectable category in which therapeutic equivalence and hospital procurement have greater influence than patent listings. [3]
A branded product may retain an Orange Book listing without retaining meaningful pricing power. Listing status is a legal-regulatory data point, not proof of a durable commercial barrier.
What formulations are protected by levoleucovorin patents?
Commercially important formulation protection is limited. Levoleucovorin is marketed primarily as an injectable solution or powder requiring preparation, depending on the product and presentation.
Potential formulation differentiation includes:
- Ready-to-use liquid versus lyophilized or reconstituted product.
- Different vial sizes.
- Concentration and fill volume.
- Stability after dilution.
- Reduced preparation time.
- Compatibility with common infusion solutions.
- Packaging designed for hospital pharmacy workflow.
These attributes can support procurement preference and reduce pharmacy labor, but they rarely create long-term exclusivity. A formulation patent would have greater value if it materially reduced preparation risk or enabled a stable ready-to-administer product. Even then, hospitals may select the lowest-cost therapeutically equivalent product unless the operational benefit is measurable.
How strong is the levoleucovorin patent estate?
The patent estate is weak from an originator-investment perspective and modest from a manufacturing-defense perspective.
| Criterion |
Assessment |
| Composition-of-matter protection |
Weak or expired |
| Method-of-use protection |
Weak or expired |
| Formulation protection |
Limited |
| Process protection |
Potentially useful but narrow |
| Regulatory exclusivity |
No current durable exclusivity |
| Generic entry barrier |
Low to moderate |
| Supply-chain barrier |
Moderate |
| Pricing protection |
Low |
| Litigation leverage |
Low |
| Life-cycle management potential |
Limited |
The most defensible value is operational rather than legal. A manufacturer with validated sterile capacity, consistent quality, national distribution, and shortage-resilient inventory may outperform a nominally stronger patent holder.
What are the market dynamics for levoleucovorin?
Levoleucovorin demand is relatively stable but price-sensitive. Use is tied to cancer-treatment volume, chemotherapy protocols, and clinical preference rather than consumer prescribing.
Institutional purchasing dominates
Hospitals, integrated delivery networks, oncology practices, group purchasing organizations, and specialty distributors control access. Purchasers evaluate:
- Acquisition cost.
- Contract discounts.
- Product availability.
- Vial utilization and wastage.
- Shelf life.
- Delivery reliability.
- FDA shortage history.
- Pharmacy preparation requirements.
The drug is administered in supervised clinical settings, so direct-to-consumer brand marketing has little effect.
Protocols support baseline demand
Levoleucovorin remains embedded in colorectal-cancer regimens involving 5-fluorouracil and in methotrexate-rescue protocols. This creates a baseline market even when price competition is intense.
Demand can shift between levoleucovorin and racemic leucovorin based on:
- Hospital protocol.
- Relative acquisition cost.
- Physician preference.
- Availability.
- Contracting terms.
- Reimbursement margin.
- Clinical interpretation of isomer-specific dosing.
Shortages can temporarily change market share
Sterile injectable shortages can produce sharp but temporary changes in product demand. When a competitor is unavailable, hospitals may accept a higher-priced branded or alternative generic product. Once supply normalizes, purchasing departments generally return to lower-cost sources.
This creates episodic revenue spikes rather than durable growth.
What is the financial trajectory for levoleucovorin?
The financial trajectory is mature, fragmented, and difficult to measure through public-company filings.
No major public company consistently reports levoleucovorin revenue as a separate line item. Branded sales have generally been included within broader oncology or specialty-pharmaceutical categories. Generic sales are often reported within larger injectable portfolios. As a result, public filings cannot support a precise standalone global revenue figure without commercial market-data subscriptions.
The economic trajectory is nonetheless clear:
| Stage |
Revenue pattern |
Margin pattern |
| Initial branded launch |
Rapid uptake from oncology accounts |
High branded gross margin |
| Early competition |
Continued volume with price pressure |
Margin compression |
| Mature generic market |
Stable or declining nominal sales |
Lower gross margin |
| Shortage periods |
Temporary volume and price increases |
Volatile margin |
| Long-term market |
Low-growth, procurement-driven sales |
Returns depend on manufacturing efficiency |
Revenue is likely to be more resilient than price. Cancer incidence and treatment volume support recurring demand, but generic entry and contracting reduce revenue per vial.
For branded suppliers, the product is most valuable as part of a broader oncology portfolio. It can support customer relationships, distributor utilization, and portfolio completeness even if standalone margins are modest. For generic manufacturers, the product is attractive when production can be integrated into an existing sterile-injectable network.
Which companies are competing in the levoleucovorin market?
The competitive field includes branded oncology suppliers and generic injectable manufacturers. Commercial participation has changed over time through licensing, acquisitions, and portfolio transfers.
Relevant commercial entities have included:
- Spectrum Pharmaceuticals, the original developer associated with Fusilev and Khapzory.
- Acrotech Biopharma, an oncology company associated with commercializing products including levoleucovorin presentations.
- Aurobindo Pharma through its U.S. and specialty-pharmaceutical operations.
- Generic injectable manufacturers, including companies with approved levoleucovorin calcium injection products.
- Hospital-distributed and specialty-pharmacy channels.
Licensing and portfolio transactions have mattered more than new molecular innovation. Rights to mature oncology injectables can move between companies when larger firms rationalize portfolios or specialty companies seek established hospital products.
What patent litigation affects levoleucovorin?
Levoleucovorin has no known litigation profile comparable with high-revenue oncology drugs such as pembrolizumab, lenalidomide, ibrutinib, or trastuzumab.
The principal legal risks are more likely to involve:
- ANDA approval timing.
- Product-labeling disputes.
- Manufacturing patents.
- Trade secrets involving sterile production.
- Supply agreements.
- Distribution rights.
- FDA enforcement involving quality systems or shortages.
For investors, the absence of major ongoing patent litigation is itself commercially relevant. It indicates that litigation is unlikely to restore branded pricing power or materially delay generic competition.
What generic entry risks exist for levoleucovorin?
Generic entry risk is already realized rather than prospective. A new generic entrant could still affect market economics by increasing supplier count or undercutting existing contracts.
The main risks to an incumbent are:
- Lower contract prices.
- Loss of hospital formulary placement.
- Reduced distributor inventory.
- Increased switching to racemic leucovorin.
- Reduced utilization of branded presentations.
- Margin erosion from competing sterile-injectable suppliers.
- Customer concentration in large health systems.
A generic entrant’s own risk is different. FDA approval alone does not guarantee sales. The entrant must secure reliable API supply, pass sterile-manufacturing inspections, maintain inventory, obtain wholesaler access, and compete for contracts that may already be locked into annual purchasing arrangements.
How does levoleucovorin compare with leucovorin?
| Factor |
Levoleucovorin |
Racemic leucovorin |
| Composition |
Active levo-isomer |
Mixture of levo- and dextro-isomers |
| Dosing |
May differ by protocol |
Established legacy dosing |
| Clinical use |
Oncology rescue and 5-FU regimens |
Broad historical use |
| Patent position |
Mature and largely expired |
Mature and largely expired |
| Generic competition |
Established |
Established |
| Pricing |
Can carry a premium in some settings |
Often lower-cost |
| Market access |
Hospital and oncology procurement |
Broad institutional access |
| Substitution |
Protocol-dependent |
Protocol-dependent |
The commercial advantage of levoleucovorin depends on whether a purchaser values isomer-specific dosing, protocol continuity, or operational consistency enough to justify any price premium.
What geographic markets matter for levoleucovorin?
The United States is commercially important because of its oncology purchasing infrastructure, reimbursement system, and branded injectable history. Europe and other developed markets also use folinic-acid products, but naming, reimbursement, formulation, and substitution rules differ.
Geographic commercial risks include:
- National reimbursement limits.
- Tender-based hospital purchasing.
- Local manufacturing requirements.
- Import restrictions.
- Sterile-product shortages.
- Different acceptance of racemic versus single-isomer products.
- Currency and distributor concentration.
A company with U.S. hospital access may have a stronger commercial position than one with a nominally broad patent portfolio but limited procurement penetration.
What is the outlook for levoleucovorin revenue?
The base case is stable-to-declining nominal revenue for branded products and low-growth revenue for generic suppliers. Unit demand should remain supported by oncology treatment volumes, while average selling prices remain under pressure.
The strongest upside scenarios involve:
- A sustained shortage affecting major competitors.
- A differentiated ready-to-use formulation.
- New hospital contracts.
- Expansion of sterile manufacturing capacity.
- A broader oncology portfolio that improves account economics.
- International tender wins.
The strongest downside scenarios involve:
- Additional generic entrants.
- Hospital conversion to lower-cost racemic leucovorin.
- Loss of a major distributor or group-purchasing contract.
- FDA manufacturing observations.
- Persistent price compression.
- Reduction in use of legacy chemotherapy regimens.
Key Takeaways
- Levoleucovorin is an FDA-approved, mature oncology injectable with no meaningful current composition-of-matter exclusivity.
- Fusilev and Khapzory established branded positions, but generic competition has removed durable pricing power.
- The Orange Book and patent estate provide limited commercial protection.
- Paragraph IV litigation is not the primary current risk because generic competition is already established.
- Biosimilars are irrelevant because levoleucovorin is a small-molecule drug.
- Hospital procurement, sterile manufacturing, supply reliability, and formulary access drive market share.
- Public companies generally do not disclose standalone levoleucovorin revenue.
- The financial trajectory is stable-to-declining for branded products, with temporary upside during shortages.
- Generic manufacturers can earn acceptable returns through efficient production and contract access, not through patent exclusivity.
- The principal commercial asset is dependable supply within a broader oncology portfolio.
FAQs
Is levoleucovorin still under patent?
No meaningful patent protection appears to support long-term market exclusivity for the active ingredient. Product-specific Orange Book listings remain the relevant legal reference.
Is levoleucovorin interchangeable with leucovorin?
They are related but not automatically interchangeable in every clinical or regulatory setting. Dosing, labeling, institutional protocols, and state or payer rules can determine substitution.
Does levoleucovorin have biosimilar competition?
No. Biosimilar regulation applies to biologic products. Levoleucovorin is a small-molecule drug and competes with generic products.
Can a new formulation of levoleucovorin command a premium?
Possibly, but the premium would depend on measurable benefits such as reduced pharmacy preparation, lower wastage, longer stability, or better shortage resilience. A formulation patent alone would not guarantee commercial adoption.
Is levoleucovorin an attractive acquisition target?
It is more attractive as part of a larger oncology injectable portfolio than as a standalone growth asset. Acquisition value depends on manufacturing capacity, hospital contracts, supply reliability, and portfolio synergies rather than on patent exclusivity.
References
-
U.S. Food and Drug Administration. (2008). Fusilev (levoleucovorin calcium) injection: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (2018). Khapzory (levoleucovorin) injection: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.
-
U.S. Food and Drug Administration. (2024). Drug shortages database. FDA.
-
U.S. Food and Drug Administration. (1984). Drug Price Competition and Patent Term Restoration Act. FDA.
-
U.S. Food and Drug Administration. (2024). Approved abbreviated new drug applications and therapeutic equivalence information. FDA.
